凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06821 凯莱英

已收盘 12-19 16:08:47

51.150

-0.750

-1.45%

最高52.700	最低50.500	成交量18.37万
今开50.800	昨收51.900	日振幅4.24%
总市值188.09亿	流通市值14.09亿	总股本3.68亿
成交额934.47万	换手率0.67%	流通股本2,755万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06821","market":"HK","secType":"STK","nameCN":"凯莱英","latestPrice":51.15,"timestamp":1734595727019,"preClose":51.9,"halted":0,"volume":183700,"delay":0,"floatShares":27553300,"shares":367718103,"eps":6.7152305,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.75,"latestTime":"12-19 16:08:47","open":50.8,"high":52.7,"low":50.5,"amount":9344674,"amplitude":0.042389,"askPrice":51.2,"askSize":300,"bidPrice":51.1,"bidSize":300,"shortable":3,"etf":0,"ttmEps":2.3189653115348126,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"listingDate":1639065600000,"adjPreClose":51.9,"dividendRate":0.03775,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":1.390318,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"002821","market":"SZ","secType":"STK","nameCN":"凯莱英","latestPrice":78.16,"timestamp":1734591801000,"preClose":78.09,"halted":0,"volume":2708293,"delay":0,"premium":"-38.99"}},"requestUrl":"/m/hq/s/06821/tweets","defaultTab":"tweets","newsList":[{"id":"2492954103","title":"凯莱英：12月16日高管张婷增持股份合计3800股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492954103","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492954103?lang=zh_cn&edition=full","pubTime":"2024-12-17 21:01","pubTimestamp":1734440466,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月17日市场公开信息、上市公司公告及交易所披露数据整理，凯莱英最新董监高及相关人员股份变动情况：2024年12月16日公司董事张婷共增持公司股份3800.0股，占公司总股本为0.001%。变动期间公司股价下跌3.75%，12月16日当日收盘报78.18元。凯莱英近半年内的董监高及核心技术人员增减持详情如下：凯莱英的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入5221.59万，融资余额增加；融券净流出600.0，融券余额减少。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121700037707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002821","06821","BK1191","LU1328615791.USD","BK0239","BK0132"],"gpt_icon":0},{"id":"2490907855","title":"12月11日凯莱英发布公告，其股东增持12.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490907855","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490907855?lang=zh_cn&edition=full","pubTime":"2024-12-11 20:01","pubTimestamp":1733918461,"startTime":"0","endTime":"0","summary":"证券之星消息，12月11日凯莱英发布公告《凯莱英:关于部分董事、高级管理人员和核心技术及业务人员增持公司A股股份实施期限过半的公告》，其股东核心技术及业务人员于2024年9月12日至2024年12月11日间合计增持12.6万股，占公司目前总股本的0.0343%，变动期间该股股价上涨35.29%，截止12月11日收盘报84.77元。股东增减持详情见下表：根据凯莱英2024年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121100034396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06821","BK1191","BK0239","LU1328615791.USD","002821","BK0132"],"gpt_icon":0},{"id":"2490885813","title":"凯莱英(002821.SZ)部分高管和核心技术及业务人员累计增持34.42万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490885813","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490885813?lang=zh_cn&edition=full","pubTime":"2024-12-11 19:41","pubTimestamp":1733917268,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英(002821.SZ)发布公告，截至公告披露日，本次增持计划实施期限已过半，公司部分董事、高级管理人员和其他核心技术及业务人员通过深圳证券交易所证券交易系统集中竞价交易方式累计增持公司股份34.42万股，占目前公司总股本的0.0936%，增持金额合计2326.38万元","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06821","BK0132","002821","LU1328615791.USD","BK0239","BK1191"],"gpt_icon":0},{"id":"2490830207","title":"凯莱英(06821)部分董事、高管和核心技术及业务人员合计增持2326.38万元的公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2490830207","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490830207?lang=zh_cn&edition=full","pubTime":"2024-12-11 19:32","pubTimestamp":1733916746,"startTime":"0","endTime":"0","summary":"公司部分董事、高级管理人员和其他核心技术及业务人员拟自增持计划公告之日起 6 个月内增持公司 A 股股份，本次增持总金额不低于人民币 2000 万元(含)。截至本公告披露日，本次增持计划实施期限已过半，公司部分董事、高级管理人员和其他核心技术及业务人员通过深圳证券交易所证券交易系统集中竞价交易方式累计增持公司股份 344,194 股，占目前公司总股本的 0.0936%，增持金额合计 2326.38 万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223711.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06821","BK0239","BK0132","002821","LU1328615791.USD"],"gpt_icon":0},{"id":"2490880679","title":"凯莱英12月11日遭主力抛售94万元 环比增加370.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490880679","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490880679?lang=zh_cn&edition=full","pubTime":"2024-12-11 16:16","pubTimestamp":1733905011,"startTime":"0","endTime":"0","summary":"12月11日, 凯莱英股价跌0.27%，报收54.90元，成交金额865万元，换手率0.57%，振幅2.91%，量比0.33。凯莱英今日主力资金净流出94万元，上一交易日主力净流出20万元，今日环比增加370.00%。该股近5个交易日上涨5.97%，主力资金累计净流入22万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出340万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211161712ab6efaef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211161712ab6efaef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","06821"],"gpt_icon":0},{"id":"2490794399","title":"港股午评|恒生指数早盘跌0.57%   CRO概念板块集体走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2490794399","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490794399?lang=zh_cn&edition=full","pubTime":"2024-12-09 12:00","pubTimestamp":1733716811,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数跌0.57%，报19753点；恒生科技指数跌0.63%。国内航线需求维持复苏态势，低基数下板块25年将迎来补偿式增长。航空股持续上行，中国国航涨7.32%；南方航空涨2.73%。金山云涨3.83%，AI布局已初见成效，三季度盈利水平加速提升。微盟集团再涨超1.84%， AI Agent迎来密集落地，公司AI商业化前景广阔。第四范式再涨超5%，先知AI平台营收增超50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0516422440.USD","BK1576","LU2045819591.USD","LU0140636845.USD","SG9999002562.SGD","LU0516423091.SGD","LU0359202008.SGD","LU0516423174.USD","LU0307460666.USD","LU0320764599.SGD","LU0348825331.USD","LU0326950275.SGD","LU0856984785.SGD","LU0417516902.SGD","LU0516422952.EUR","LU1242518857.USD","IE00B0JY6N72.USD","HSI","BK1191","LU2125910500.SGD","BK1141","BK1610","HSCEI","BK1521","LU0052750758.USD","SG9999002463.SGD","02359","LU1794554557.SGD","LU0051755006.USD","513600","LU0819121731.USD","LU0823426480.USD","LU0979878070.USD","HSTECH","06821","LU0327786744.USD","LU1688375341.USD","02833","LU0359201612.USD","YANG","MCHmain","LU0516422366.SGD","LU0823426308.USD","BK1589","LU0708995583.HKD","02269","07226","LU0417516738.SGD","LU0572944931.SGD","HHImain"],"gpt_icon":1},{"id":"2490762210","title":"凯莱英(06821)上涨6.56%，报58.5元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490762210","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490762210?lang=zh_cn&edition=full","pubTime":"2024-12-09 09:30","pubTimestamp":1733707844,"startTime":"0","endTime":"0","summary":"12月9日，凯莱英(06821)盘中上涨6.56%，截至09:30，报58.5元/股，成交151.44万元。凯莱英医药集团是一家全球领先的CDMO公司，主要为全球新药提供从临床早期到商业化阶段的一站式研发、生产服务，包括高级中间体、原料药、制剂的研发和cGMP生产，以及临床研究服务。公司通过持续技术创新和战略合作，为国内外制药公司、生物技术公司提供药品全生命周期一站式CMC服务，加快新药开发及应用，逐步构建起创新药一体化服务生态圈。截至2024年三季报，凯莱英营业总收入40.91亿元、净利润7.1亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/09093046152735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","06821","002821","BK1191","LU1328615791.USD","BK0132"],"gpt_icon":0},{"id":"2490776741","title":"凯莱英盘中异动 早盘快速拉升6.56%报58.500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490776741","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490776741?lang=zh_cn&edition=full","pubTime":"2024-12-09 09:30","pubTimestamp":1733707818,"startTime":"0","endTime":"0","summary":"2024年12月09日早盘09时30分，凯莱英股票出现异动，股价急速拉升6.56%。截至发稿，该股报58.500港元/股，成交量3600股，换手率0.01%，振幅2.19%。资金方面，该股资金流入2.343万港元，流出4.057万港元。凯莱英股票所在的药品行业中，整体涨幅为0.22%。其相关个股中，康龙化成、凯莱英、联康生物科技集团涨幅较大，振幅较大的相关个股有联邦制药、联康生物科技集团、凯莱英，振幅分别为4.97%、3.08%、2.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209093018971ca642&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209093018971ca642&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","06821"],"gpt_icon":0},{"id":"2490901767","title":"港股概念追踪|生物安全法案未被列入NDAA最新版本   机构看好CXO板块底部机会（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2490901767","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490901767?lang=zh_cn&edition=full","pubTime":"2024-12-09 09:29","pubTimestamp":1733707775,"startTime":"0","endTime":"0","summary":"美国当地时间2024年12月7日，美国国会参众两院军事委员会公布了2025财年国防授权法案最终协议文本，该版本兼顾了众议院以及参议院两方的提案。NDAA最新版本显示，生物安全法案未被列入其中。当地时间12月5日， 专注于生物制药行业的美国新闻媒体Endpoints报道，消息人士称，立法者正在考虑对针对生物安全法案的立法进行妥协，该立法将增加行政部门的审查，而不是直接禁止生物制药公司与中国公司合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0516422366.SGD","02359","LU0359202008.SGD","LU1720050803.USD","06821","LU1794554557.SGD","LU2242644610.SGD","YANG","LU0039217434.USD","BK1583","BK1610","LU0043850808.USD","BK1576","LU0516423091.SGD","LU0307460666.USD","LU1046422090.SGD","LU0348735423.USD","LU0979878070.USD","NDAA","LU0588546209.SGD","02269","LU0417516738.SGD","LU0348825331.USD","LU0456827905.SGD","LU1242518857.USD","07226","HSCEI","BK1191","LU0140636845.USD","LU0052750758.USD","LU2039709279.SGD","LU0572944931.SGD","LU0181495838.USD","LU1242518931.SGD","BK1141","BK1521","LU0708995583.HKD","LU0516423174.USD","LU1880383366.USD","HSTECH","BK1589","CXO","LU0856984785.SGD","LU0051755006.USD","LU2125910500.SGD","LU0417516902.SGD","LU2045819591.USD","LU0516422440.USD","LU0823426480.USD","LU0359201612.USD"],"gpt_icon":1},{"id":"2490762688","title":"A股CRO概念股开涨，德展健康涨停，睿智医药涨超13%，百花医药，药明康德、康龙化成、博腾股份、凯莱英等集体高开。","url":"https://stock-news.laohu8.com/highlight/detail?id=2490762688","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490762688?lang=zh_cn&edition=full","pubTime":"2024-12-09 09:27","pubTimestamp":1733707637,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU2045819591.USD","BK1583","BK0239","03759","603259","LU0052750758.USD","159982","002821","02359","BK1141","LU2242644610.SGD","BK0060","300363","300759","LU0708995583.HKD","LU0456842615.SGD","LU0320764599.SGD","LU1997245177.USD","06821","BK0102","BK0028","000813","BK0114","LU1997245094.SGD","BK1576","300149","600721","BK1191","BK0132","LU2125910500.SGD","399300","BK0077","LU2488822045.USD","BK0216","LU1328615791.USD","LU1046422090.SGD"],"gpt_icon":0},{"id":"2489408970","title":"凯莱英涨7.10%，国金证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2489408970","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489408970?lang=zh_cn&edition=full","pubTime":"2024-12-06 16:09","pubTimestamp":1733472553,"startTime":"0","endTime":"0","summary":"今日凯莱英涨7.10%，收盘报84.9元。2024年10月30日，国金证券研究员袁维发布了对凯莱英的研报《三季度边际改善，看好公司底部反转》，该研报对凯莱英给出“买入”评级。研报中预计公司2024/2025/2026年归母净利润分别为10.33/11.95/13.97亿元，EPS分别为2.81/3.25/3.8元，公司股票现价对应PE估值为30/26/22倍，维持“买入”评级。此外，平安证券研究员倪亦道,叶寅，财信证券研究员吴号近期也对该股发布了研报，同样给出“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120600026010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002821","06821"],"gpt_icon":0},{"id":"2489115471","title":"传美国考虑修改生物安全法案 增加对相关公司行政审查环节而非自动禁止生物制药公司与中国公司合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2489115471","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489115471?lang=zh_cn&edition=full","pubTime":"2024-12-06 14:40","pubTimestamp":1733467208,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股集体冲高，药明康德(02359)涨10%，康龙化成(03759)涨7.98%，药明生物(02269)涨6.2%，凯莱英(06821)涨5.95%，昭衍新药(06127)涨5.73%。消息面上，有媒体报道美国生物安全法称，美国立法者正考虑对法案进行更改，妥协版本内容包括增加对相关公司行政审查环节，而非自动禁止生物制药公司与中国公司合作。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949147","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","LU0516422366.SGD","06127","LU0417516738.SGD","LU1688375341.USD","LU0043850808.USD","LU0307460666.USD","LU0819121731.USD","02359","LU2125910500.SGD","SG9999002463.SGD","LU0039217434.USD","LU0456846285.SGD","LU0823426308.USD","IE00B0JY6N72.USD","LU0516423174.USD","LU0572944931.SGD","LU0708995583.HKD","LU0823426480.USD","LU0327786744.USD","LU0516422952.EUR","BK1576","02269","LU2045819591.USD","BK1583","LU0856984785.SGD","LU0140636845.USD","LU0320764599.SGD","LU0348825331.USD","BK1191","LU0052750758.USD","LU1794554557.SGD","LU2039709279.SGD","06821","LU0051755006.USD","LU0979878070.USD","LU1242518857.USD","LU0348735423.USD","LU0417516902.SGD","LU1242518931.SGD","LU0359202008.SGD","LU0456827905.SGD","LU0516423091.SGD","SG9999002562.SGD","LU2242644610.SGD","LU0588546209.SGD","LU1720050803.USD","03759","LU1046422090.SGD","LU0516422440.USD"],"gpt_icon":0},{"id":"2489424233","title":"凯莱英(06821)上涨5.07%，报53.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2489424233","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489424233?lang=zh_cn&edition=full","pubTime":"2024-12-06 11:53","pubTimestamp":1733457218,"startTime":"0","endTime":"0","summary":"12月6日，凯莱英(06821)盘中上涨5.07%，截至11:53，报53.9元/股，成交2188.43万元。凯莱英医药集团是一家全球领先的CDMO公司，主要为全球新药提供从临床早期到商业化阶段的一站式研发、生产服务，包括高级中间体、原料药、制剂的研发和cGMP生产，以及临床研究服务。公司通过持续技术创新和战略合作，为国内外制药公司、生物技术公司提供药品全生命周期一站式CMC服务，加快新药开发及应用，逐步构建起创新药一体化服务生态圈。截至2024年三季报，凯莱英营业总收入40.91亿元、净利润7.1亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/06115346089472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["002821","06821","LU1328615791.USD","BK1191","BK0132","BK0239"],"gpt_icon":0},{"id":"2489427956","title":"凯莱英盘中异动 急速上涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489427956","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489427956?lang=zh_cn&edition=full","pubTime":"2024-12-06 11:53","pubTimestamp":1733457211,"startTime":"0","endTime":"0","summary":"2024年12月06日临近午盘11时53分，凯莱英股票出现波动，股价大幅拉升5.07%。截至发稿，该股报53.900港元/股，成交量41.25万股，换手率1.50%，振幅4.78%。机构评级方面，在所有13家参与评级的机构中，77%的券商给予买入建议，8%的券商给予持有建议，15%的券商给予卖出建议。凯莱英股票所在的药品行业中，整体涨幅为0.16%。其相关个股中，衍生集团、康龙化成、凯莱英涨幅较大，振幅较大的相关个股有德琪医药-B、康龙化成、凯莱英，振幅分别为10.45%、7.68%、4.68%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206115336ab618840&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206115336ab618840&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06821","BK1191"],"gpt_icon":0},{"id":"2489492422","title":"凯莱英(06821)股价上升5.068%，现价港币$53.9","url":"https://stock-news.laohu8.com/highlight/detail?id=2489492422","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489492422?lang=zh_cn&edition=full","pubTime":"2024-12-06 11:53","pubTimestamp":1733457180,"startTime":"0","endTime":"0","summary":"[上升股]凯莱英(06821) 股价在上午11:53比前收市价上升5.068%，现股价为港币$53.9。至目前为止，今日最高价为$53.9，而最低价为$51.45。总成交量为40.95万股，总成交金额为港币$2.172千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2412063172/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1328615791.USD","06821","BK0239","002821","BK0132","BK1191"],"gpt_icon":0},{"id":"2488156892","title":"“立根中国资产·破岩2025”第九届智通财经资本市场年会活动报名中！","url":"https://stock-news.laohu8.com/highlight/detail?id=2488156892","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488156892?lang=zh_cn&edition=full","pubTime":"2024-12-04 15:43","pubTimestamp":1733298208,"startTime":"0","endTime":"0","summary":"12月11日上午9：00-12:00：第九届智通财经资本市场年会暨上市公司颁奖典礼汇聚国内外顶尖金融机构代表与首席经济学家，300+港美股上市公司高管，共议资本市场投资热点话题，共同剖析大变局下资产价值波动的逻辑动因，把脉2025年中国资产投资机遇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02190","01783","02509","01651","00826","01450","01773","02273","09959","02411","00033","09616","00666","01117","00861","03709","09860","00003","00855","03306","06821","06633","03700","09919","02105","00086","01907","02268","09955","09885","01600","02362","01378","03877","00363","01313","00020","01672","09878","06682","01083","06680","02498","01969","00552","02858","06830","00857","00992","02158"],"gpt_icon":0},{"id":"2488243769","title":"凯莱英获得发明专利授权：“转氨酶突变体及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2488243769","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488243769?lang=zh_cn&edition=full","pubTime":"2024-12-04 02:20","pubTimestamp":1733250050,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示凯莱英新获得一项发明专利授权，专利名为“转氨酶突变体及其应用”，专利申请号为CN202210764588.2，授权日为2024年12月3日。今年以来凯莱英新获得专利授权12个，较去年同期增加了140%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120400003138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06821","LU1328615791.USD","BK0132","002821","BK1191","BK0239"],"gpt_icon":0},{"id":"2488960748","title":"凯莱英12月03日遭主力抛售220万元 环比增加478.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488960748","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488960748?lang=zh_cn&edition=full","pubTime":"2024-12-03 16:16","pubTimestamp":1733213799,"startTime":"0","endTime":"0","summary":"12月03日, 凯莱英股价涨1.24%，报收52.90元，成交金额2464万元，换手率1.69%，振幅2.30%，量比2.45。凯莱英今日主力资金净流出220万元，连续3日净流出，上一交易日主力净流出38万元，今日环比增加478.95%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为40.00%，平均跌幅为2.04%。该股近5个交易日上涨4.13%，主力资金累计净流出278万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出435万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203161718a268c27c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203161718a268c27c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06821","BK1191"],"gpt_icon":0},{"id":"2488996427","title":"医药外包概念普升 药明生物(02269)涨7.48% 机构指CRO/CDMO明年可能逐步走出明显拐点","url":"https://stock-news.laohu8.com/highlight/detail?id=2488996427","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488996427?lang=zh_cn&edition=full","pubTime":"2024-12-03 15:41","pubTimestamp":1733211718,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药外包概念普升，药明生物 涨7.48%，药明康德涨6.12%，康龙化成涨2.8%，金斯瑞生物科技涨1.87%，凯莱英涨1.44%。板块内部来看，在医保预付金、医保目录发布等政策催化下，医药商业、创新药子板块均有不错表现。该行表示，今年来看，原料药、低耗、上游的部分个股率先表现出了一定改善，展望明年，原料药、低耗的趋势有望持续，CRO/CDMO、上游、ICL、设备招投标可能逐步走出明显拐点。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1948872","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","CDMO","HK0000306685.HKD","LU0417516738.SGD","LU1688375341.USD","LU0359201612.USD","BK1610","02359","159938","HK0000306701.USD","SG9999002463.SGD","LU0039217434.USD","LU0456846285.SGD","01548","IE00B0JY6N72.USD","LU0572944931.SGD","LU0823426480.USD","LU0327786744.USD","BK1574","LU0516422952.EUR","BK1576","LU0181495838.USD","02269","BK1583","LU0856984785.SGD","LU0140636845.USD","HK0000320264.USD","LU0320764599.SGD","BK1191","LU0052750758.USD","LU1794554557.SGD","BK4139","06821","LU0051755006.USD","BK1589","LU0979878070.USD","HK0000320223.HKD","09939","LU0417516902.SGD","LU0359202008.SGD","LU0456827905.SGD","LU0516423091.SGD","BK1161","SG9999002562.SGD","LU2242644610.SGD","LU0588546209.SGD","LU1720050803.USD","03759","LU1046422090.SGD","LU0516422440.USD"],"gpt_icon":0},{"id":"2488608246","title":"凯莱英(06821.HK)累计回购1,230.07万A股  总额近10亿人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2488608246","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488608246?lang=zh_cn&edition=full","pubTime":"2024-12-02 23:46","pubTimestamp":1733154360,"startTime":"0","endTime":"0","summary":"凯莱英(06821.HK) 公布，11月29日止，累计回购1,230.07万股A股，占总股本3.6161%；每股作价介乎71.65-102元人民币，总金额约9.996亿人民币。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-02 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220106150434741_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220106150434741_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1401202/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["399300","BK0132","159982","BK0239","BK1191","002821","LU1328615791.USD","06821"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.asymchem.com","stockEarnings":[{"period":"1week","weight":-0.0546},{"period":"1month","weight":-0.0317},{"period":"3month","weight":0.1585},{"period":"6month","weight":0.0308},{"period":"1year","weight":-0.4045},{"period":"ytd","weight":-0.4085}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.1018},{"period":"1year","weight":0.2035},{"period":"ytd","weight":0.1653}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"凯莱英医药集团（天津）股份有限公司是一家主要从事提供医药外包一站式综合服务的中国公司。该公司的业务包括小分子药物定制研发生产（CDMO）、化学大分子CDMO、临床研究服务、制剂CDMO、生物大分子CDMO、技术输出和合成生物技术。该公司的产品类别涵盖多肽、寡核苷酸、单克隆抗体、抗体偶联药物和信使RNA等。该公司主要在国内外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.132759},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.013478},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.042104},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.117331},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.056981},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.006579},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.032115},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.037196},{"month":9,"riseRate":0.666667,"avgChangeRate":0.190591},{"month":10,"riseRate":0,"avgChangeRate":-0.11689},{"month":11,"riseRate":0.666667,"avgChangeRate":0.030863},{"month":12,"riseRate":0.666667,"avgChangeRate":0.024147}],"exchange":"SEHK","name":"凯莱英","nameEN":"ASYMCHEM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯莱英(06821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯莱英,06821,凯莱英股票,凯莱英股票老虎,凯莱英股票老虎国际,凯莱英行情,凯莱英股票行情,凯莱英股价,凯莱英股市,凯莱英股票价格,凯莱英股票交易,凯莱英股票购买,凯莱英股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯莱英(06821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}